Current status of adjuvant therapy after surgical resection for patients with hepatocellular carcinoma and microvascular invasion
10.3760/cma.j.cn113884-20220316-00112
- VernacularTitle:肝细胞癌伴微血管侵犯患者手术切除后辅助治疗现状
- Author:
Yuanquan ZHAO
1
;
Guoqi XU
;
Jie CHEN
Author Information
1. 广西医科大学附属肿瘤医院肝胆外科，南宁 530021
- Keywords:
Carcinoma, hepatocellular;
Hepatectomy;
Neoadjuvant therapy;
Microvascular invasion
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(11):868-872
- CountryChina
- Language:Chinese
-
Abstract:
Hepatectomy and liver transplantation are the most effective radical treatment for patients with hepatocellular carcinoma, but the high recurrence rate after surgery which seriously affects the prognosis of patients cannot be ignored. Microvascular invasion (MVI) is a risk factor for postoperative recurrence and metastasis in patients with hepatocellular carcinoma. There is no consensus or guideline recommendation locally or intermutually on postoperative adjuvant therapy of patients with hepatocellular carcinoma with MVI. Appropriate selection of postoperative adjuvant therapy is worth more in-depth discussion. This article reviews recent and relevant studies on postoperative adjuvant therapy for patients with hepatocellular carcinoma and MVI, including local anti-tumor therapy, systemic chemotherapy, immunotherapy, targeted therapy and combination therapy, with the aim to provide better reference to clinicians in managing these patients with postoperative adjuvant therapy.
